183 related articles for article (PubMed ID: 19356014)
61. Irinotecan for metastatic colorectal cancer.
Med Lett Drugs Ther; 1997 Jan; 39(992):8. PubMed ID: 9008684
[No Abstract] [Full Text] [Related]
62. Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.
Sai K; Saito Y; Maekawa K; Kim SR; Kaniwa N; Nishimaki-Mogami T; Sawada J; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Ohe Y; Yamada Y; Tamura T; Yoshida T; Matsumura Y; Ohtsu A; Saijo N; Minami H
Cancer Chemother Pharmacol; 2010 May; 66(1):95-105. PubMed ID: 19771428
[TBL] [Abstract][Full Text] [Related]
63. Effects of ABCC2 and SLCO1B1 Polymorphisms on Treatment Responses in Thai Metastatic Colorectal Cancer Patients Treated with Irinotecan-Based Chemotherapy.
Treenert A; Areepium N; Tanasanvimon S
Asian Pac J Cancer Prev; 2018 Oct; 19(10):2757-2764. PubMed ID: 30360603
[TBL] [Abstract][Full Text] [Related]
64. Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1.
de With M; van Doorn L; Kloet E; van Veggel A; Matic M; de Neijs MJ; Oomen-de Hoop E; van Meerten E; van Schaik RHN; Mathijssen RHJ; Bins S
Clin Pharmacokinet; 2023 Nov; 62(11):1589-1597. PubMed ID: 37715926
[TBL] [Abstract][Full Text] [Related]
65. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
Paoluzzi L; Singh AS; Price DK; Danesi R; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
J Clin Pharmacol; 2004 Aug; 44(8):854-60. PubMed ID: 15286088
[TBL] [Abstract][Full Text] [Related]
66. Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular Assay.
Hasegawa Y; Ando Y; Shimokata K
Expert Rev Mol Diagn; 2006 Jul; 6(4):527-33. PubMed ID: 16824027
[TBL] [Abstract][Full Text] [Related]
67. Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan.
Salvador-Martín S; García-González X; García MI; Blanco C; García-Alfonso P; Robles L; Grávalos C; Pachón V; Longo F; Martínez V; Sanjurjo-Sáez M; López-Fernández LA
Pharmacol Res; 2018 Oct; 136():133-139. PubMed ID: 30213564
[TBL] [Abstract][Full Text] [Related]
68. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer.
Zhou Q; Sparreboom A; Tan EH; Cheung YB; Lee A; Poon D; Lee EJ; Chowbay B
Br J Clin Pharmacol; 2005 Apr; 59(4):415-24. PubMed ID: 15801936
[TBL] [Abstract][Full Text] [Related]
69. Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.
Lu YY; Huang XE; Wu XY; Cao J; Liu J; Wang L; Xiang J
Asian Pac J Cancer Prev; 2014; 15(7):3335-41. PubMed ID: 24815493
[TBL] [Abstract][Full Text] [Related]
70. The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.
Choi BS; Alberti DB; Schelman WR; Kolesar JM; Thomas JP; Marnocha R; Eickhoff JC; Ivy SP; Wilding G; Holen KD
Cancer Chemother Pharmacol; 2010 Oct; 66(5):973-80. PubMed ID: 20127092
[TBL] [Abstract][Full Text] [Related]
71. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y
Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391
[TBL] [Abstract][Full Text] [Related]
72. Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray.
Tsunedomi R; Hazama S; Okayama N; Oka M; Nagano H
Cancer Sci; 2017 Jul; 108(7):1504-1509. PubMed ID: 28474802
[TBL] [Abstract][Full Text] [Related]
73. Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy.
Yu QQ; Qiu H; Zhang MS; Hu GY; Liu B; Huang L; Liao X; Li QX; Li ZH; Yuan XL
World J Gastroenterol; 2016 Apr; 22(16):4250-8. PubMed ID: 27122675
[TBL] [Abstract][Full Text] [Related]
74. [Genetic marker of statin-induced rhabdomyolysis].
Chiba K; Morimoto K
Yakugaku Zasshi; 2011 Feb; 131(2):247-53. PubMed ID: 21297370
[TBL] [Abstract][Full Text] [Related]
75. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.
Ando Y; Ueoka H; Sugiyama T; Ichiki M; Shimokata K; Hasegawa Y
Ther Drug Monit; 2002 Feb; 24(1):111-6. PubMed ID: 11805731
[TBL] [Abstract][Full Text] [Related]
76. [Irinotecan and liver dysfunctions].
Sablin MP; Le Tourneau C; Faivre S; Raymond E
Therapie; 2007; 62(2):111-5. PubMed ID: 17582311
[TBL] [Abstract][Full Text] [Related]
77. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
[TBL] [Abstract][Full Text] [Related]
78. Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.
van der Bol JM; Loos WJ; de Jong FA; van Meerten E; Konings IR; Lam MH; de Bruijn P; Wiemer EA; Verweij J; Mathijssen RH
Eur J Cancer; 2011 Apr; 47(6):831-8. PubMed ID: 21216137
[TBL] [Abstract][Full Text] [Related]
79. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
[No Abstract] [Full Text] [Related]
80. [CPT-11: new drug for metastatic colorectal cancer].
Barone C; Pozzo C; Cassano A
Tumori; 1999; 85(6):A1-11. PubMed ID: 10774581
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
